Amneal Pharmaceuticals Files Prospectus Related To The Offer And Sale Of Up To 28,942,098 Shares of Class A Common Stock By Selling Stockholders
https://www.sec.gov/Archives/edgar/data/1723128/000114036126035617/ny20081412x1_s3asr.htm
Stocks · News reference
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target
JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.
Emergent BioSolutions Receives ~$24M Contract Modification From Biomedical Advanced Research And Development Authority For Strategic Preparedness Response Within U.S. Department Of Health And Human Services To Provide CYFENDUS
Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for
Emergent BioSolutions Receives Canada's Offer To Provide NARCAN Nasal Spray, Effective Oct. 1 Through September 2029
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply NARCAN® Nasal Spray. The standing offer
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report
JP Morgan Reinstates Underweight on Emergent BioSolutions
JP Morgan analyst Jessica Fye reinstates Emergent BioSolutions (NYSE:EBS) with a Underweight.